Vimarsana
Biggest News Aggregation in the World

Multiple Ascending Dose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple Ascending Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Ascending Dose Today - Breaking & Trending Today

IRLAB Therapeutics: IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757 - Vimarsana News

IRLAB Therapeutics: IRLAB has Administered the First Dose in a Phase I Clinical Trial with the Drug Candidate IRL757

GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and

IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757 - Vimarsana News

IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757

IRLAB Therapeutics AB announced that dosing has been initiated in a Phase I study of the drug candidate IRL757. IRL757 has been shown in preclinical disease models to counteract apathy - a condition...

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11 - Vimarsana News

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

MIAMI, FL, April 25, 2024 -- Veru Inc. , a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and...

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease -February 27, 2024 at 02:01 pm EST - Vimarsana News

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease -February 27, 2024 at 02:01 pm EST

BETHESDA, Md., Feb. 27, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule...

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis - Vimarsana News

Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

GHENT, Belgium, December 14, 2023--Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Source: yahoo.com